Lonza strengthens its bioconjugation capacities at Visp, in the canton of Valais, with two new manufacturing suites.
Lonza to Expand Bioconjugation in Visp, with Two Additional Manufacturing Suites Read More »
Final deadline for submitting applications to the Innosuisse call for projects for the Flagship Initiative 2024, focusing on Artificial Intelligence in Life Sciences, with an emphasis on healthcare.
Call for projects AI in Life Sciences – Flagship Initiative Read More »
Precise Health, a biotech start-up based at the Energypolis Campus in Sion, has just won phase 2 of the national Venture Kick competition. The CHF 40,000 prize will enable the company to further develop its technology, which is revolutionizing the treatment of antibiotic-resistant bacterial infections.
Valais start-up Precise Health wins CHF 40,000 Venture Kick prize Read More »
Lonza is expanding its partnership with an undisclosed major pharmaceutical company to supply antibody-drug conjugates (ADCs). This agreement includes building a new facility at Lonza’s Ibex® Biopark in Visp (Valais), Switzerland, and providing large-scale production of monoclonal antibodies for a new ADC treatment.
Lonza builds new plant in Visp, creating 100 new jobs Read More »
From lab bench to pitch perfection : Ninsun’s cancer-fighting innovation just lit up the Innothèque at Foire du Valais last Friday for the Startup Pitch of the Fondation the Ark !
Ninsun is winning the Fondation the Ark’s Startup Pitch Read More »
The “Innovation in the vineyards” event, held on September 30th at the Innothèque space during the Foire du Valais, was a resounding success, attracting over thirty participants. Organized in collaboration with PhytoArk, this event highlighted the technological advancements and innovations transforming the viticulture sector.
Highlights from the “Innovation in the vineyards” Event Read More »
On 23 September 2024, ten23 health celebrated the inauguration of its VIVA2® facility in Visp, in the vicinity of our BioArk Visp technology site, bringing to fruition an ambitious project announced in June 2022. This new state-of-the-art infrastructure considerably strengthens the region’s production capacity for sterile medicines.
Swiss contract development and manufacturing organization ten23health has achieved B Corp certification, recognizing its commitment to social and environmental responsibility in the pharmaceutical industry.
ten23health Becomes First Sterile Product CDMO to Earn B Corp Certification Read More »
Since its launch in 2006, Valais-based Lugaia has gone from strength to strength. It has now established itself as a major player in the global market for containment solutions. Company owner Viktor Schnyder explains what makes Lugaia tick and how the company benefits from its location in the Valais. Lugaia has a history stretching back
Valaisan SME Lugaia rides the wave of success with its niche products Read More »
We’re thrilled to announce that CEIDOS, a start-up, based at our BioArk Monthey technology site, has just been endorsed by the Innosuisse Innovation Council, securing significant funding! With a total budget of 1.2 million francs, their C-Netics technology will be enhanced in partnership with CSEM and HES-SO Valais-Wallis. This project will perfect their online monitoring
CEIDOS secures support from Innosuisse in partnership with CSEM & HES-SO Valais-Wallis Read More »
